Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-506 in hematological malignancies
NCT06387082Phase 1Recruiting
- Sponsor
- HUTCHMED
- Start
- May 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HMPL-506 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM) (13 arms), sponsored by HUTCHMED. Primary endpoints: Dose-limiting Toxicity at 4 weeks, Serious Adverse Events at 42 months and 1 more. Started May 2024; status: recruiting.
02
Drugs
HMPL-506
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06387082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06387082.